Increasing precision beyond A/T/N:Identification of molecular subtypes of Alzheimer's disease using CSF Proteomics
This study confirms the existence of distinct molecular subtypes of AD that stratify patients beyond A/T/N, corroborating findings by Tijms et al. (2024) & Moutinho et al. (2024). Further validation of these subtypes in additional cohorts and clinical trials, alongside the development of blood based biomarkers, will help to further enhance the precision of AD diagnosis, prognosis, and treatment.
Authors
- Liping Hou (ORCID: https://orcid.org/0000-0003-3972-245X)
- Asif Imran Emon (ORCID: https://orcid.org/0000-0002-2331-5174)
- Jingyue Xi
- Christopher D. Whelan (ORCID: https://orcid.org/0000-0003-0308-5583)
- Pablo García‐González (ORCID: https://orcid.org/0000-0003-0125-5403)
- Shuwei Li (ORCID: https://orcid.org/0000-0001-7176-1964)
- Bart Smets (ORCID: https://orcid.org/0000-0001-8480-0782)
- A. Ballano Ruiz
- Alfredo Cabrera Socorro
- Raquel Puerta
- Yanfei Zhang
- Amanda Cano
Institutions
- Johnson & Johnson (United States) (US)
- Janssen (Belgium) (BE)
- The University of Texas at San Antonio Health Science Center (US)
- University of Wuppertal (DE)
- Universitat Internacional de Catalunya (ES)
- Institute for Neurodegenerative Disorders (US)
- Fundació ACE (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_102872
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00